Key Points
- CEO Bahija Jallal sold 11,474 shares on Feb. 18 at an average price of $32.35 for total proceeds of $371,183.90, leaving her with 12,343 shares (a ~48.18% reduction); the trade was disclosed in an SEC Form 4 filing.
- Market and analyst context: IMCR traded near $32.40 (52‑week range $23.15–$40.71) with a $1.64B market cap and negative P/E, while analysts' consensus is a "Moderate Buy" with an average target of $60.90.
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) CAO John Goll sold 698 shares of the company's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $22,580.30. Following the completion of the sale, the chief accounting officer owned 653 shares of the company's stock, valued at $21,124.55. This represents a 51.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Immunocore Stock Down 2.0%
Shares of Immunocore stock traded down $0.67 during trading on Friday, hitting $32.50. 127,005 shares of the stock traded hands, compared to its average volume of 455,268. The company has a current ratio of 6.00, a quick ratio of 5.97 and a debt-to-equity ratio of 0.99. The stock's fifty day simple moving average is $33.89 and its 200 day simple moving average is $34.30. The firm has a market cap of $1.64 billion, a P/E ratio of -57.02 and a beta of 0.78. Immunocore Holdings PLC Sponsored ADR has a 52-week low of $23.15 and a 52-week high of $40.71.
Hedge Funds Weigh In On Immunocore
Hedge funds have recently modified their holdings of the stock. Primecap Management Co. CA increased its holdings in shares of Immunocore by 5.5% in the fourth quarter. Primecap Management Co. CA now owns 3,961,880 shares of the company's stock valued at $137,517,000 after purchasing an additional 207,320 shares during the period. Bellevue Group AG grew its position in Immunocore by 14.5% during the third quarter. Bellevue Group AG now owns 2,796,803 shares of the company's stock valued at $101,608,000 after buying an additional 354,973 shares during the period. Tang Capital Management LLC increased its holdings in Immunocore by 14.0% in the fourth quarter. Tang Capital Management LLC now owns 2,628,538 shares of the company's stock valued at $91,237,000 after buying an additional 322,930 shares in the last quarter. Millennium Management LLC raised its position in shares of Immunocore by 334.3% in the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company's stock worth $45,993,000 after acquiring an additional 974,463 shares during the period. Finally, Armistice Capital LLC boosted its position in Immunocore by 33.3% during the fourth quarter. Armistice Capital LLC now owns 1,098,000 shares of the company's stock worth $38,112,000 after purchasing an additional 274,000 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research note on Wednesday, February 4th. Wall Street Zen cut Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday, January 31st. UBS Group set a $55.00 price target on Immunocore and gave the company a "buy" rating in a report on Wednesday, January 7th. Zacks Research upgraded Immunocore from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, January 7th. Finally, Wells Fargo & Company started coverage on Immunocore in a research note on Friday, October 31st. They issued an "overweight" rating and a $60.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $60.90.
View Our Latest Analysis on IMCR
Trending Headlines about Immunocore
Here are the key news stories impacting Immunocore this week:
- Positive Sentiment: Analyst coverage and institutional ownership point to upside: several brokers maintain positive outlooks (examples cited include UBS and Wells Fargo) and the consensus average price target remains well above the current price (~$60.90 average target reported), while institutional ownership is high (~84.5%), which can support share stability and long-term demand. MarketBeat IMCR Coverage
- Neutral Sentiment: Strong liquidity on the balance sheet: Immunocore shows very healthy current and quick ratios (~6.00 and ~5.97), which reduces short-term solvency risk but is unlikely to drive near-term share moves by itself. Trading volume today was well below average, which can amplify price moves on news. (No definitive short-interest signal — reported short-interest data appears inconsistent/buggy and should be treated cautiously.)
- Negative Sentiment: Significant insider selling: CEO Bahija Jallal sold 11,474 shares at an average of $32.35 (≈$371k), reducing her stake by ~48%. Multiple other insiders (including David M. Berman, CAO John Goll and Tina Leger) also sold large portions of their holdings on the same day. Such clustered insider dispositions can be read negatively by the market and put downward pressure on the stock. InsiderTrades: CEO Sells IMCR SEC Form 4 (Berman)
About Immunocore
(
Get Free Report)
Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body's own T‐cell response to treat cancer and infectious diseases. The company's proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.
The company's most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
